RJA
CTMX icon

Raymond James & Associates’s CytomX Therapeutics CTMX Stock Holding History

Raymond James & Associates’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-8,515
Closed -$242K – 3604
2018
Q1 		$242K Buy
+8,515
New +$243K ﹤0.01% 3030

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Raymond James & Associates's CTMX Position: Q2 2018 in Review

Raymond James & Associates sold out of CytomX Therapeutics (CTMX) in Q2 2018, closing a stake of 8,515 shares — an estimated $242K sold.

Raymond James & Associates first reported a position in CTMX in Q1 2018 and held it in 1 quarter. The position peaked at $242K in Q1 2018. 142 funds tracked by Wall St. Rank hold CTMX as of Q2 2018.

  • Raymond James & Associates reported no remaining CytomX Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Raymond James & Associates sold 8,515 CytomX Therapeutics shares in Q2 2018, an estimated $242K.
  • Raymond James & Associates first reported a position in CytomX Therapeutics in Q1 2018 and held it in 1 quarter.
  • Raymond James & Associates's CytomX Therapeutics position peaked at $242K in Q1 2018.
  • 142 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2018.

Based on Raymond James & Associates's 13F filing for Q2 2018, filed 14 Aug 2018.